Bio-Techne (TECH) Price & Analysis

Compare

514 Followers

TECH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$46.01 - $80.95

Previous CloseN/A

Volume102.39K

Average Volume (3M)2.34M

Market Cap

$8.50B

Enterprise Value$8.25B

Total Cash (Recent Filing)$162.19M

Total Debt (Recent Filing)$444.06M

Price to Earnings (P/E)118.9

Beta0.92

Next Earnings

Nov 04, 2025

EPS Estimate

0.43

Last Dividend Ex-Date

Aug 18, 2025

Dividend Yield0.6%

Share Statistics

EPS (TTM)0.53

Shares Outstanding155,549,590

10 Day Avg. Volume1,967,127

30 Day Avg. Volume2,336,293

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue6.77

Enterprise Value/Gross Profit10.44

Enterprise Value/Ebitda36.99

Forecast

1Y Price Target

$66.00

Price Target Upside23.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Financial PerformanceThe financial results showed a slight beat on revenue and profitability metrics were better than expected.

Organic GrowthTechne is considered one of the best-positioned companies to see growth despite uncertainties.

Strategic DivestituresThe recent divestiture of ExoDx allows Bio-Techne to free up capital, improve margins, and invest further in its strategic growth areas.

Bears Say

Growth OutlookManagement expects organic growth to be in the low single digits due to macro uncertainties.

Macro HeadwindsShares traded down due to macro headwinds such as NIH, pharma tariffs, and biotech funding challenges.

Policy UncertaintiesManagement's preliminary guidance came as a surprise with lower than expected growth projections due to ongoing policy uncertainties.

Bio-Techne News

Bio-Techne upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital upgraded Bio-Techne (TECH) to Outperform from Sector Perform with a $73 price target Published first on...

2d ago

TECH

Bio-Techne upgraded to Outperform at RBC on forecast multiple expansion

As previously reported, RBC Capital analyst Conor McNamara upgraded Bio-Techne (TECH) to Outperform from Sector Perform with a...

2d ago

TECH

CoreWeave upgraded, Instacart downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

14d ago

ALC

Bio-Techne upgraded to Buy from Neutral at Citi

Citi upgraded Bio-Techne (TECH) to Buy from Neutral with a price target of $70, up from $55. The...

14d ago

TECH

Bio-Techne reports Q4 adjusted EPS 53c, consensus 50c

Reports Q4 revenue $316.96M, consensus $314.7M. “Bio-Techne (TECH) delivered a solid fourth quarter that was in-line with our...

29d ago

TECH

Bio-Techne to divest Exosome Diagnostics business to Mdxhealth

Bio-Techne (TECH) announced an agreement where Mdxhealth (MDXH) will acquire its Exosome Diagnostics business, including the ExoDx Prostate...

30d ago

MDXH

TECH

Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TECH stock, giving a Buy rating today....

28d ago

TECH

Bio-Techne’s Strong Q4 Performance and Strategic Moves Justify Buy Rating

Bio-Techne, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brandon Couillard from Wells...

28d ago

TECH

Bio-Techne Reports Solid Q4 2025 Results Amid Strategic Shift

Bio-Techne ( ($TECH) ) has released its Q4 earnings. Here is a breakdown of the information Bio-Techne presented...

29d ago

TECH

Bio-Techne’s Earnings Call: Growth Amid Challenges

Bio-Techne (($TECH)) has held its Q4 earnings call. Read on for the main highlights of the call. Bio-Techne’s...

29d ago

TECH

Bio-Techne Divests Exosome Diagnostics to Boost Growth

Bio-Techne ( ($TECH) ) has issued an update. Bio-Techne reported its fourth quarter fiscal 2025 results, highlighting a...

29d ago

TECH

Bio-Techne price target raised to $58 from $51 at Baird

Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Bio-Techne (TECH) to $58 from $51 and...

1M ago

TECH

Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher

TD Cowen analyst Kyle Boucher maintained a Buy rating on Bio-Techne today and set a price target of...

1M ago

TECH

Bio-Techne resumed with an Overweight at Stephens

Stephens analyst Steven Etoch resumed coverage of Bio-Techne (TECH) with an Overweight rating and $65 price target The...

1M ago

TECH

TECH FAQ

What was Bio-Techne’s price range in the past 12 months?

Bio-Techne lowest stock price was $46.01 and its highest was $80.95 in the past 12 months.

What is Bio-Techne’s market cap?

Bio-Techne’s market cap is $8.50B.

When is Bio-Techne’s upcoming earnings report date?

Bio-Techne’s upcoming earnings report date is Nov 04, 2025 which is in 61 days.

How were Bio-Techne’s earnings last quarter?

Bio-Techne released its earnings results on Aug 06, 2025. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.499 by $0.031.

Is Bio-Techne overvalued?

According to Wall Street analysts Bio-Techne’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bio-Techne pay dividends?

Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.6%. See more information on Bio-Techne dividends here

What is Bio-Techne’s EPS estimate?

Bio-Techne’s EPS estimate is 0.43.

How many shares outstanding does Bio-Techne have?

Bio-Techne has 155,549,590 shares outstanding.

What happened to Bio-Techne’s price movement after its last earnings report?

Bio-Techne reported an EPS of $0.53 in its last earnings report, beating expectations of $0.499. Following the earnings report the stock price went down -8.724%.

Which hedge fund is a major shareholder of Bio-Techne?

Currently, no hedge funds are holding shares in TECH

Bio-Techne Stock Smart Score

Underperform

Fundamentals

Return on Equity

3.68%

Trailing 12-Months

Asset Growth

-9.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bio-Techne

Bio-Techne Corporation (TECH) is a leading developer and manufacturer of high-quality biotechnology products and solutions. The company operates in the life sciences sector, focusing on providing innovative tools and reagents to researchers and clinicians worldwide. Bio-Techne's core offerings include proteins, antibodies, immunoassays, and instruments used in scientific research, diagnostics, and therapeutic development.

Bio-Techne (TECH) Earnings & Revenues

Historic Earnings Reports

TECH Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

Bio-Techne's earnings call highlighted solid performance in the biopharma sector and strategic moves to enhance profitability, but also underscored challenges in academia and uncertainties in the biotech funding environment. The divestiture of Exosome Diagnostics is expected to improve margins, while potential tariff impacts and NIH funding uncertainties pose risks.View all TECH earnings summaries

TECH Net revenue Breakdown

71.35% Protein Sciences

28.39% Diagnostics and Genomics

0.34% Other

TECH Stock 12 Month Forecast

Average Price Target

$66.00

▲(23.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","78":"$78","54.75":"$54.8","62.5":"$62.5","70.25":"$70.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,54.75,62.5,70.25,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.42,55.08,56.74,58.4,60.06,61.72,63.38,65.04,66.7,68.36,70.02,71.68,73.34,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.42,54.38769230769231,55.355384615384615,56.323076923076925,57.29076923076923,58.25846153846154,59.22615384615385,60.19384615384615,61.16153846153846,62.12923076923077,63.096923076923076,64.06461538461538,65.0323076923077,{"y":66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.42,53.38769230769231,53.355384615384615,53.323076923076925,53.29076923076923,53.25846153846154,53.22615384615385,53.19384615384615,53.16153846153846,53.12923076923077,53.096923076923076,53.06461538461539,53.03230769230769,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.59,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >